Market News & Trends
Gerresheimer Presents New COP Syringes Produced in Germany: Gx RTF ClearJect
On the occasion of this year's customer trade show, Gerresheimer Pharma Days held in Chicago, Illinois, the company presented the first product of its…
New Merger Between Pfizer & Anacor Set to Leverage Companies in Atopic Dermatitis Space
An upcoming merger agreement between Pfizer and Anacor, worth around $5.2 billion, could boost the marketing power of Anacor’s lead pipeline candidate, crisaborole, and pave…
LIPOPHILIC SALTS - Opportunities & Applications in Oral Drug Delivery
Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.
US FDA Grants Fast-Track Designation to Novavax's Vaccine
Novavax, Inc. recently announced the US FDA has granted Fast-Track Designation to Novavax’ RSV F-Protein nanoparticle vaccine candidate (RSV F Vaccine) for the protection of…
Pernix Therapeutics Announces the Issuance of Three New Orange Book Patents
Pernix Therapeutics Holdings, Inc. recently announced that the United States Patent and Trademark Office has issued US Patent Numbers 9,339,499, 9,326,982, and 9,333,201, covering important…
Innocoll Announces Positive Phase III Trial Results
Innocoll recently announced that two placebo-controlled Phase III pivotal studies evaluating XARACOLL (bupivacaine-collagen bioresorbable implant) each achieved the primary endpoint as a post-operative pain relief…
Iceni Pharmaceuticals Launches as New Company
Iceni Pharmaceuticals recently announced its launch as a new company, focusing on developing repurposed and reformulated cancer therapies. The company’s lead product Cilcane (generic name…
Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid PDC With Paclitaxel
Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid PDC With Paclitaxel Cellectar Biosciences, Inc. recently announced the United States Patent and Trademark Office has…
The Promise of Stem Cell Research Yields Double-Digit Growth Rates
Although products based on stem cells have yet to form an established market, unlike some other potential applications of bioscience, stem cell technology has already…
New Vasculitis Drug Set to Address a Number of Major Unmet Needs
ChemoCentryx’s CCX168, an orally administered small molecule in development for the treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), has strong potential to address…
Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC Research reveals in its new…
REGENXBIO & Biogen Enter Exclusive License Agreement
REGENXBIO Inc. recently announced an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on the NAV Technology Platform…
Lonza CytoSMART Lab Free-Trial Initiative Launched
Any laboratory wanting to experience Lonza’s CytoSMART System can now apply to become a Lonza CytoSMART Lab. In this exciting new initiative, Lonza is offering…
Juniper Pharma Strengthens Topicals Capability
Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc., has reinforced its early stage topical and semi-solids capability by investing in a Becomix homogenizer mixer.…
Hebei Changshan Biochem Pharma & Albumedix Enter Development Agreement
Albumedix and Hebei Changshan Biochem Pharma Co. recently announced they have entered into a supply agreement for the development of a novel type II diabetes…
New Company Created to Develop Novel Technology to Treat Diabetes
The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, recently announced the creation of Islexa, a new company developing a novel technology…
Aptar Pharma Provides Unit-Dose Nasal Spray Technology for Opioid Overdose
Aptar Pharma recently announced it has provided the delivery system and regulatory support for Adapt Pharma’s Narcan, which is the first US FDA-approved nasally administered,…
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx’s Orally Administered Complement 5aR Inhibitor
Vifor Pharma and ChemoCentryx, Inc. recently announced that Vifor Pharma has licensed rights to commercialize CCX168, a Complement 5a Receptor (C5aR) inhibitor ready for Phase…
Vetter is a Winner of AbbVie TRIUMPH AWARD
AbbVie, one of the world’s leading biopharmaceutical companies has awarded Vetter, a leading contract manufacturing and development organization (CDMO), the TRIUMPH AWARD for 2015. The…
LDC & Boehringer Ingelheim Join Forces to Discover Novel Approach for Schizophrenia Treatment
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH and Boehringer Ingelheim International GmbH have signed an agreement providing Boehringer Ingelheim with the option…
